Lagano Roxanne, an executive at Zoetis Inc., recently reported a transaction involving phantom stock units. This filing is significant as it underscores the company's approach to executive compensation, which often includes stock-based incentives.
Background
Lagano Roxanne is associated with Zoetis Inc., a company that operates in the pharmaceutical preparations sector. The recent filing, dated October 13, 2026, is part of a series of reports by Lagano, indicating ongoing transactions related to executive compensation. The company is listed under the Central Index Key 0001555280.
What the Filing Says
The filing details a transaction on October 9, 2026, involving 367.7875 phantom stock units at a price of $26.17 per unit. Following this transaction, Lagano Roxanne now owns a total of 31,314.6485 shares. The filing states, "These phantom stock units, which were acquired pursuant to the Zoetis Supplemental Savings Plan, are settled in cash following the reporting person's separation from service." This highlights the structure of executive compensation at Zoetis.
Impact
This transaction may affect various stakeholders, including Zoetis employees, shareholders, and competitors in the pharmaceutical industry. The use of phantom stock units as part of compensation packages can influence executive retention and performance, which, in turn, impacts the company's overall strategy and market position.
What's Next
The filing does not say what happens next.